benzyl-[[3-[1-[3-[(benzylammonio)methyl]-5-[1-[3-[(benzylammonio)methyl]-5-[1-[3-[(benzylammonio)methyl]-2,4-dihydroxy-5-(4-hydroxybutyl)phenyl]-4-hydroxy-butyl]-2,4-dihydroxy-phenyl]-4-hydroxy-butyl]-2,4-dihydroxy-phenyl]-4-hydroxy-butyl]-2,6-dihydroxy-phenyl]methyl]ammonium;tetrachloride

ID: ALA5270342

Chembl Id: CHEMBL5270342

Max Phase: Preclinical

Molecular Formula: C72H90Cl4N4O12

Molecular Weight: 1199.50

Associated Items:

Names and Identifiers

Canonical SMILES:  Cl.Cl.Cl.Cl.OCCCCc1cc(C(CCCO)c2cc(C(CCCO)c3cc(C(CCCO)c4ccc(O)c(CNCc5ccccc5)c4O)c(O)c(CNCc4ccccc4)c3O)c(O)c(CNCc3ccccc3)c2O)c(O)c(CNCc2ccccc2)c1O

Standard InChI:  InChI=1S/C72H86N4O12.4ClH/c77-32-14-13-26-51-36-56(68(84)62(66(51)82)44-74-40-48-20-7-2-8-21-48)53(28-16-34-79)58-38-60(72(88)64(70(58)86)46-76-42-50-24-11-4-12-25-50)54(29-17-35-80)59-37-57(69(85)63(71(59)87)45-75-41-49-22-9-3-10-23-49)52(27-15-33-78)55-30-31-65(81)61(67(55)83)43-73-39-47-18-5-1-6-19-47;;;;/h1-12,18-25,30-31,36-38,52-54,73-88H,13-17,26-29,32-35,39-46H2;4*1H

Standard InChI Key:  UFDLWNXESLMZFJ-UHFFFAOYSA-N

Associated Targets(Human)

CRYAA Tchem Alpha-crystallin A chain (85 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 1199.50Molecular Weight (Monoisotopic): 1198.6242AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Twum K, Bhattacharjee A, Laryea ET, Esposto J, Omolloh G, Mortensen S, Jaradi M, Stock NL, Schileru N, Elias B, Pszenica E, McCormick TM, Martic S, Beyeh NK..  (2021)  Functionalized resorcinarenes effectively disrupt the aggregation of αA66-80 crystallin peptide related to cataracts.,  12  (12.0): [PMID:35028562] [10.1039/D1MD00294E]

Source